ArticleJournal of diabetes investigation2025
Clinical value of high-frequency ultrasound and serum miR-92a-3p in diabetic peripheral neuropathy.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
AIMS/
introductionCross-sectional area (CSA) by high-frequency ultrasound (HF-US) detects morphologic changes in neuropathy. microRNA (miR)-92a-3p is linked to diabetes and nerve damage. Our study evaluated the diagnostic use of CSAs along with miR-92a-3p in diabetic peripheral neuropathy (DPN) and its relationship to the condition. MATERIALS AND
methodsA total of 172 patients were enrolled, comprising 89 with DPN and 83 T2DM cases without DPN. Real-time quantitative polymerase chain reaction (RT-qPCR) was utilized to quantify serum miR-92a-3p levels. HF-US detected CSA in the median, ulnar, and tibial nerves. Logistic regression analyzed potential risk factors for DPN occurrence and severity. Receiver operating characteristic curves assessed the diagnostic significance of miR-92a-3p and CSAs for DPN. Pearson coefficients evaluated the correlation between the Toronto Clinical Scoring System (TCSS) score and miR-92a-3p or CSAs.
resultsDPN patients had significantly higher serum miR-92a-3p levels and CSAs of the median, tibial, and ulnar nerves than T2DM patients. Moreover, miR-92a-3p and CSAs were risk factors for DPN. When combined, they yielded an AUC of 0.891, with 80.90% sensitivity and 91.57% specificity, accurately identifying DPN patients. Furthermore, miR-92a-3p and CSAs correlated with TCSS score and were higher in moderate-to-severe patients with DPN than in mild patients with DPN. Finally, miR-92a-3p combined with CSAs predicted moderate-to-severe DPN with 91.67% sensitivity and 85.37% specificity.
conclusionsSerum miR-92a-3p and CSAs of median, ulnar, and tibial nerves are elevated in DPN patients. Their combination has high diagnostic significance in identifying DPN in T2DM patients and assessing its severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.